Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon
Banner ASC in Sun City, Arizona.

PAD patients fare better when they have a strong support system

PAD patients with a strong social support system were associated with better outcomes in a new analysis published in the Journal of Vascular Surgery.

The U.S. Food and Drug Administration (FDA) has announced that Inari Medical is recalling its ClotTriever XL catheter for removing blood clots and other blockages from large blood vessels. The news comes after the FDA received several reports of “serious adverse events” due to the device becoming entrapped or blocking arteries in the patient’s lungs. Six deaths and four other patient injuries have been associated with the issue so far.

FDA announces recall of Inari Medical catheter after 6 deaths, 4 injuries

The FDA ruled that this is a Class I recall due to the significant risks for patients. Customers are not required to return the devices, however. Inari Medical has provided updated warnings and recommendations that should be followed. 

pharmaceutical drug approval process

Drugmaker to ‘challenge’ FDA after only receiving tentative approval for inhaled PAH treatment

An exclusivity agreement is stopping Liquidia Corporation from gaining full FDA approval of its new inhalation powder for pulmonary arterial hypertension. The company said it is disappointed with the agency's decision and plans to "take quick action."

Images coronary calcium imaging by optical coherence tomography (OCT) and high-definition intravascular ultrasound (IVUS).

OCT-guided PCI improves survival after life-threatening heart attacks

Researchers explored data from nearly 4,000 STEMI patients, noting that optical coherence tomography may be a valuable first step of any treatment strategy. 

healthcare value value-based care money dollar

Medical device startup exits stealth mode to name CEO, announce $21M in funding

Jupiter Endovascular, a new subsidiary of Neptune Medical, aims to "bring the precision and control of direct surgical access to catheter-based interventions.”  

Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S

LAAO with Watchman FLX associated with positive 1-year outcomes, real-world data confirm

Researchers hoped to gain a better understanding of the device's real-world impact by reviewing registry data from more than 97,000 U.S. patients. Overall, the Watchman FLX was linked to positive data and limited adverse events one year after treatment. 

Treating mitral regurgitation with transcatheter mitral edge-to-edge repair (TEER) using the MitraClip device is associated with a low risk of cerebrovascular accidents (CVAs) such as stroke and transient ischemic attack (TIA), according to new data published in The American Journal of Cardiology.[1]

TEER with Abbott’s MitraClip linked to low stroke risk, new study confirms

Treating severe MR with the popular device does not appear to increase a patient's risk of stroke or transient ischemic attack. When patients present with AFib, however, care teams may want to make certain adjustments to optimize outcomes. 

Boston Scientific's Sentinel Cerebral Protection System during a TAVR procedure

Cerebral protection during TAVR linked to lower risk of major stroke, other key benefits

Using a cerebral protection device during TAVR was associated with lower readmission rates, shorter hospital stays—and, yes, a lower risk of patients suffering a major stroke. A team of specialists with Cleveland Clinic shared their new findings in the Journal of the American Heart Association.

Displaying 25 - 32 of 1638

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.